JP2012515540A - 抗体混合物を産生するための方法 - Google Patents

抗体混合物を産生するための方法 Download PDF

Info

Publication number
JP2012515540A
JP2012515540A JP2011546813A JP2011546813A JP2012515540A JP 2012515540 A JP2012515540 A JP 2012515540A JP 2011546813 A JP2011546813 A JP 2011546813A JP 2011546813 A JP2011546813 A JP 2011546813A JP 2012515540 A JP2012515540 A JP 2012515540A
Authority
JP
Japan
Prior art keywords
region
replaced
nucleic acid
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011546813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515540A5 (enExample
Inventor
ポール パレン
ヨースト ジェイ． ネイセン
アラン フランク ラブレイン
ジャニーヌ スフールマン
トム フィンク
デ ウィンケル ヤン バン
ステファン ロベリクス
イグナス ラスター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2012515540A publication Critical patent/JP2012515540A/ja
Publication of JP2012515540A5 publication Critical patent/JP2012515540A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011546813A 2009-01-26 2010-01-26 抗体混合物を産生するための方法 Ceased JP2012515540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900118 2009-01-26
DKPA200900118 2009-01-26
PCT/EP2010/050822 WO2010084197A1 (en) 2009-01-26 2010-01-26 Methods for producing mixtures of antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016052035A Division JP2016165285A (ja) 2009-01-26 2016-03-16 抗体混合物を産生するための方法

Publications (2)

Publication Number Publication Date
JP2012515540A true JP2012515540A (ja) 2012-07-12
JP2012515540A5 JP2012515540A5 (enExample) 2013-03-14

Family

ID=42060888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546813A Ceased JP2012515540A (ja) 2009-01-26 2010-01-26 抗体混合物を産生するための方法
JP2016052035A Pending JP2016165285A (ja) 2009-01-26 2016-03-16 抗体混合物を産生するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016052035A Pending JP2016165285A (ja) 2009-01-26 2016-03-16 抗体混合物を産生するための方法

Country Status (6)

Country Link
US (1) US20120020952A1 (enExample)
EP (1) EP2389392A1 (enExample)
JP (2) JP2012515540A (enExample)
CN (2) CN104262483A (enExample)
SG (1) SG172977A1 (enExample)
WO (1) WO2010084197A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515482A (ja) * 2014-05-13 2017-06-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
CN107108747A (zh) * 2015-01-08 2017-08-29 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN101983968B (zh) * 2010-09-26 2013-03-06 浙江海洋学院 乌贼墨寡肽的酶解制备方法
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
JP6031735B2 (ja) * 2011-06-13 2016-11-24 ソニー株式会社 情報処理装置、情報処理方法およびコンピュータプログラム
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501856A (ja) * 2002-10-09 2006-01-19 インテグリジェン， インコーポレイテッド 組換え触媒ポリペプチドおよびその使用
JP2006515503A (ja) * 2002-07-18 2006-06-01 クルセル ホランド ベー ヴェー 抗体混合物の組換え生産
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
EP3663318A1 (en) * 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515503A (ja) * 2002-07-18 2006-06-01 クルセル ホランド ベー ヴェー 抗体混合物の組換え生産
JP2006501856A (ja) * 2002-10-09 2006-01-19 インテグリジェン， インコーポレイテッド 組換え触媒ポリペプチドおよびその使用
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515482A (ja) * 2014-05-13 2017-06-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
US10385119B2 (en) 2014-05-13 2019-08-20 Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US10647758B2 (en) 2014-05-13 2020-05-12 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
JP2020141697A (ja) * 2014-05-13 2020-09-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
US10975140B2 (en) 2014-05-13 2021-04-13 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
JP2021121217A (ja) * 2014-05-13 2021-08-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
JP7229298B2 (ja) 2014-05-13 2023-02-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
CN107108747A (zh) * 2015-01-08 2017-08-29 苏州康宁杰瑞生物科技有限公司 具有共同轻链的双特异性抗体或抗体混合物
JP2018504113A (ja) * 2015-01-08 2018-02-15 蘇州康寧傑瑞生物科技有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
US10808043B2 (en) 2015-01-08 2020-10-20 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific antibody or antibody mixture with common light chains
JP7041516B2 (ja) 2015-01-08 2022-03-24 江蘇康寧杰瑞生物制薬有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
US11396557B2 (en) 2015-01-08 2022-07-26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific antibody or antibody mixture with common light chains

Also Published As

Publication number Publication date
CN102365296A (zh) 2012-02-29
SG172977A1 (en) 2011-08-29
JP2016165285A (ja) 2016-09-15
CN104262483A (zh) 2015-01-07
EP2389392A1 (en) 2011-11-30
US20120020952A1 (en) 2012-01-26
WO2010084197A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
JP2016165285A (ja) 抗体混合物を産生するための方法
US20240002495A1 (en) Human anti-il-33 neutralizing monoclonal antibody
KR102482710B1 (ko) 항-pd-1 항체, 이의 생산 방법 및 사용 방법
US12331115B2 (en) Uses of anti-SIRPg antibodies
JP7620780B2 (ja) Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
JP2024511642A (ja) 新規ｔｎｆｒ２結合分子
US20240409625A9 (en) Engineered dual binding antibodies and uses thereof
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
WO2023093899A1 (zh) 经修饰的蛋白或多肽
US20230242640A1 (en) ANTI-SIRPg Compounds
KR101804988B1 (ko) 신규 항-tfpi 항체 및 이를 포함하는 조성물
US20230374148A1 (en) Binding molecules that multimerise cd45
WO2025077822A1 (en) Anti-tslp antibodies and uses thereof
HK40130678A (en) Tumor necrosis factor receptor agonistic mbs
WO2023138639A1 (zh) 靶向tigit的抗原结合蛋白及其用途
JP2026515973A (ja) Ｎｋｐ８０に結合するｎｋ細胞エンゲージャー及びその用途
HK40130679A (en) Multivalent and multispecific cytokine antagonists
AU2023407261A1 (en) Tumor necrosis factor receptor agonistic mbs
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도
CN118679183A (zh) 特异性拮抗剂抗sirpg抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160316

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160525

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160926